Trials NCT05305911, NCT04363697, and NCT04509674 are currently ongoing to assess the effects of the in-hospital initiation of SGLT2 inhibitors Dapagliflozin and Empagliflozin in addition to a standard therapeutic regimen after an MI on the outcome of HF hospitalizations, MACE, and all-cause mortality. The gene discussed is SLC5A2; the disease is hydrops fetalis.